Vanguard Capital Management
CTXR icon

Vanguard Capital Management’s Citius Pharmaceuticals CTXR Stock Holding History

Vanguard Capital Management’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$119K Buy
197,364
+29,626
+18% +$20.1K ﹤0.01% 3865
2026
Q1 		$151K Buy
+167,738
New +$135K ﹤0.01% 3827

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
BW
BostonPremier Wealth Hanover, Massachusetts $235M AUM 31.01% 1-Year Est. Return

Vanguard Capital Management's CTXR Position: Q2 2026 in Review

Vanguard Capital Management increased its Citius Pharmaceuticals (CTXR) stake by 18% in Q2 2026, buying an estimated $20.1K and bringing the position to 197,364 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3865.

Vanguard Capital Management first reported a position in CTXR in Q1 2026 and has held it in 2 quarters since. The position peaked at $151K in Q1 2026. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Vanguard Capital Management held 197,364 shares of Citius Pharmaceuticals worth $119K as of Q2 2026.
  • Vanguard Capital Management bought 29,626 Citius Pharmaceuticals shares in Q2 2026, an estimated $20.1K.
  • Citius Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3865 holding.
  • Vanguard Capital Management first reported a position in Citius Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Citius Pharmaceuticals position peaked at $151K in Q1 2026.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.